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The platinum-based compound cisplatin is among the most widely
used and effective anti-cancer drugs currently available (Kelland,
1993). However, its activity is limited by the fact that many
tumours are intrinsically resistant or develop resistance during
therapy, and by its neuro- and nephrotoxicity. Several platinum
analogues that are able to circumvent cisplatin resistance, and/or
the severe side-effects of cisplatin, are currently under clinical
evaluation (Christian, 1992). Oxaliplatin is one of the 1,2-
diaminocyclohexane (DACH) carrier ligand-based groups of plat-
inum drugs (Chaney, 1995). Like other DACH-based platinum
compounds, oxaliplatin has shown lack of cross-resistance in
several cisplatin-resistant tumour cell lines (Los et al, 1990;
Schmidt and Chaney, 1993). Cytotoxicity of platinum drugs is
believed to result from the formation of platinum—DNA adducts.
Eukaryotic cells respond to the presence of cisplatin and oxali-
platin adducts in DNA by activating signal transduction pathways
that result in cell cycle arrest, an increase in DNA repair activity
and apoptosis (Eastman, 1990; Woynarowski et al, 1997). There
are no data available on what signalling pathways are activated by
oxaliplatin, and only few data with respect to cisplatin. Recent
studies have shown that the cisplatin-induced injury response
involves activation of the stress-activated protein kinase (SAPK,
also known as c-Jun NH2-terminal kinase or JNK) and the nuclear
c-Abl protein tyrosine (Liu et al, 1996a; Kharbanda et al, 1997;
Nehme et al, 1997). The JNK kinases are a family of p54/p46
serine threonine kinases that are related to the MAP kinase family
(Derijard et al, 1995). JNK kinases phosphorylate the three nuclear
transcription factors, including c-Jun, ATF2 and Elk-1, and stimu-
late their transcriptional activities (Hibi et al, 1993; Cavigelli et al,
1995; Gupta et al, 1995). The product of the c-abl gene is a non-
receptor tyrosine kinase that shares structural features with the Src
family of tyrosine kinases (Wang, 1993). The SH3 domain of c-
Abl binds to DNA-dependent protein kinase (Kharbanda et al,
1997) and RNA polymerase II (Baskaran et al, 1996), which have
been identified as c-Abl substrates. Activation of the JNK and c-
Abl kinases by DNA damage may constitute an initial step in the
generation of signals that coordinate the full injury response.
Loss of DNA mismatch repair has been observed in a wide
variety of tumours (Orth et al, 1994). These cancers include most
tumours associated with hereditary non-polyposis colorectal
cancer (HNPCC), as well as a significant fraction of sporadic
colon, gastric, pancreatic, endometrial, ovarian and small-cell lung
carcinomas. The genes that encode proteins with roles in DNA
mismatch repair in humans include the MutS homologues
hMSH2, hMSH3, hMSH6 (GTBP/p160) and the MutL homo-
logues hMLH1, hPMS1 and hPMS2 (Kolodner, 1996; Fishel and
Wilson, 1997).
We have previously reported on the drug sensitivities of several
pairs of cell lines molecularly engineered to differ with respect to
DNA mismatch repair capacity. The hMLH1-deficient HCT116
and HCT116+ch2 cells were twofold resistant to cisplatin
compared with the repair-proficient subline HCT116+ch3 that
expresses a wild-type copy of hMLH1 (Aebi et al, 1996; Fink et al,
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the HEC59 DNA mismatch repair-deficient cells and the proficient
HEC59+ch2 subline that expresses a wild-type copy of hMSH2.
However, for neither cell pair was there a difference in sensitivity to
oxaliplatin (Fink et al, 1996). The difference in cisplatin sensitivity
was not due to a difference in the amount of drug taken up into the
cells or the extent of DNA platination after a 1-h exposure to
100 mM cisplatin (Aebi et al, 1997). It was also not due to a differ-
ence in the ability of cisplatin to induce expression of p53 (Nehme
et al, 1997). However, cisplatin activated JNK kinase more effi-
ciently in DNA mismatch repair-proficient than in repair-deficient
cells, and activation of c-Abl was completely absent from the DNA
mismatch repair-deficient cells (Nehme et al, 1997). In contrast
with the situation for cisplatin, loss of DNA mismatch repair due to
deficiency of either hMLH1 or hMSH2, was found not to produce
resistance to oxaliplatin (Fink et al, 1996; Fink et al, 1997). Failure
of loss of DNA mismatch repair to cause resistance to oxaliplatin
appeared to be linked to failure of the DNA mismatch repair
proteins to recognize this type of adduct and form complexes on
platinated DNA in gel shift assays (Fink et al, 1996).
It is our hypothesis that the DNA mismatch repair proteins serve
as a detector for cisplatin but not oxaliplatin adducts, because loss
of mismatch repair function results in resistance to the former but
not the latter. In order to serve as a detector, the mismatch repair
system must be able to initiate activation of proapoptotic
signalling pathways. Indeed, hMSH2, either by itself (Mello et al,
1996) or in conjunction with hMSH6 (Duckett et al, 1996), has
been shown to bind to DNA platinated by cisplatin. If this hypoth-
esis is correct, it should be possible to identify the signal trans-
duction pathways with which the detector communicates by
comparing pathways differentially activated during the cisplatin-
but not oxaliplatin-induced cellular injury response in mismatch
repair-proficient and -deficient cells. Therefore, we investigated
the effect of loss of DNA mismatch repair on the activation of the
JNK and c-Abl kinases in response to cisplatin- and oxaliplatin-
induced cellular injury. We report here that, unlike cisplatin, oxali-
platin does not produce differential activation of JNK and c-Abl
kinases in DNA mismatch repair-proficient and -deficient cells.
METHODS
Cell lines and culture
The hMLH1-deficient human colorectal adenocarcinoma cell line
HCT116 was obtained from the American Type Culture Collection
(ATCC CCL 247, Rockville, MD, USA), a subline into which a
wild-type copy of hMLH1 on chromosome 3 had been introduced
by microcell fusion (HCT116+ch3) and a subline that received
chromosome 2 as a negative control (HCT116+ch2) were obtained
from Drs C.R. Boland and M. Koi (Koi et al, 1994). The hMSH2-
deficient human endometrial adenocarcinoma cell line HEC59
(Umar et al, 1994) and a subline complemented with chromosome
2 containing a wild-type copy of hMSH2 (HEC59 + ch2) were also
obtained from Dr C.R. Boland and M. Koi (Umar et al, 1997). All
cell lines were maintained in Iscove￿s modified Dulbecco medium
(Irvine Scientific, Irvine, CA, USA) supplemented with 100 mM
L-glutamine and 10% heat-inactivated fetal bovine serum. The
chromosome-complemented lines were grown in medium supple-
mented with geneticin (400 mgm l —1 for HCT116+ch2 and
HCT116+ch3, and 600 mg ml—1 for HEC59 + ch2) (Gibco BRL,
Gaithersburg, MD, USA). Western blot was used to document
expression of hMLH1 and hMSH2 proteins in each of the cell lines
(data not shown). The c-abl-null mouse fibroblasts (3T3-Abl—/—),
the polyclonal populations of reconstituted 3T3-Abl+ cells and the
3T3 mock infected cells (3T3-mock) were obtained from Dr JYJ
Wang (Liu et al, 1996a). The 3T3-Abl+ and 3T3-mock cells were
obtained, respectively, by infection and selection of 3T3-Abl—/—
cells with c-abl or empty recombinant retroviruses containing the
hygromycin resistance gene. The 3T3-mock cells were used as a
negative control in all the experiments. All cell lines were main-
tained in Dulbecco￿s modified Eagle medium (Irvine Scientific)
supplemented with 100 mM L-glutamine and 10% heat-inactivated
fetal bovine serum. The absence or presence of expression of c-
Abl in 3T3-Abl—/—, 3T3-mock, and 3T3-Abl+ fibroblasts was veri-
fied by immunoblot analysis (data not shown).
Reagents
Oxaliplatin was a gift from Debiopharm (Lausanne, Switzerland);
a stock solution of 1 mM was prepared in water and kept at —20°C.
Cisplatin was obtained from Bristol—Myers Squibb Co., Princeton,
NJ, USA; a stock solution of 1 mg ml—1 was prepared in 0.9%
sodium chloride.
Immunoprecipitations
Cells growing in log phase were treated with cisplatin for 1 h at
their respective IC90 concentrations (25 mM for the HCT116 cells
and 14 mM for the HEC59 cells), or with oxaliplatin for 1 h at their
IC90 concentrations (30 mM for the HCT116 and HEC59 cells). At
2 h after the beginning of the drug exposure, cells were lysed in
1 ml of lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM sodium
chloride, 5 mM EDTA, 1% Triton X-100, 5 mM dithiothreitol,
1m M sodium vanadate, 0.1 mM phenylmethylsulphonyl fluoride
and 5 mM aminocaproic acid) for 30 min on ice. The insoluble
material was removed by centrifugation at 30 000 g for 20 min
at 4°C. Equal amounts of protein were incubated with protein
A-Sepharose and anti-JNK1 (2.5 mg) (C-17, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), or anti-Abl (2.5 mg) (K-12,
Santa Cruz Biotechnology).
JNK1 kinase assay
The method described by Derijard et al (1994) was used to deter-
mine JNK1 kinase activity. Anti-JNK1 immune complexes were
washed twice with lysis buffer and then once with kinase buffer
(20 mM Hepes, pH 7.0, 10 mM magnesium chloride, 10 mM
manganese chloride, 2 mM DTT and 0.1 mM sodium vanadate).
Immune complexes were then resuspended in 30 ml of kinase
buffer containing 5 mCi [g-32P]ATP (3000 Ci mmol—1; NEN,
Boston, MA, USA), 20 mM cold ATP, and 2.5 mg of glutathione
S-transferase (GST)-c-Jun (1—79) as substrate (Santa Cruz
Biotechnology) and incubated for 20 min at 30°C. To terminate
reaction, sodium dodecyl sulphate (SDS) sample butter was added
and samples were boiled for 5 min. The phosphorylated proteins
were resolved by 10% SDS-PAGE and visualized by autoradiog-
raphy. Anti-JNK1 immunoprecipitates were examined for their
JNK1 content by immunoblotting with JNK1 antibody (C-17,
Santa Cruz Biotechnology). The antigen—antibody complexes
were visualized by enhanced chemiluminescence (Amersham,
Arlington Heights, IL, USA).
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c-Abl kinase assay
The method described by Baskaran et al (1996) was used to deter-
mine c-Abl kinase activity. In brief, anti-Abl immune complexes
were washed with lysis buffer/500 mM sodium chloride, lysis
buffer/100 mM sodium chloride and lysis buffer alone and then
washed twice with kinase buffer containing (25 mM Tris-HCl,
pH 7.4, 10 mM magnesium chloride, and 1 mM DTT). The washed
pellet was resuspended in 20 ml of kinase buffer with 50 mCi of
[g-32P]ATP (3000 Ci mmol—1; NEN), 10 mM cold ATP, and 1 mg of
GST-CTD as substrate and incubated for 30 min at room tempera-
ture. Reactions were terminated by the addition of the SDS sample
buffer and boiling for 5 min. Phosphoproteins were fractionated
by 5—15% SDS-PAGE and visualized by autoradiography. The
amounts of c-Abl protein in the anti-Abl immunoprecipitates were
determined by immunoblotting with anti-Abl (8E9, Pharmingen,
San Diego, CA, USA). The antigen—antibody complexes were
visualized by enhanced chemiluminescence.
Cytotoxicity assays
3T3-Abl—/—, 3T3-mock, and 3T3-Abl+ mouse fibroblasts do not
form discrete colonies. Therefore, sulphorhodamine B growth rate
assays were performed by seeding fibroblasts into 96-well plates at
a density of 1500 cells per well in 100 ml of medium. After 24 h,
appropriate concentrations of cisplatin or oxaliplatin were added in
a final volume of 100 ml of medium, and the cells were exposed for
1 h. Thereafter, the drug-containing medium was aspirated and
new drug free medium was added. After 72 h, growth was stopped
by adding 50 ml of 50% (w/v) trichloroacetic acid, and cellular
protein was stained with sulphorhodamine B and was measured by
spectrophotometry (Skehan et al, 1990). Control plates were fixed
to estimate the cellular protein at time 0 (T0). The relative growth
rate R was calculated as previously reported (Monks et al, 1991). If
T ‡ T0, R = (T — T0)/(C — T0); if T < T0, R = (T — T0/T0; with T being
the absorbance at 72 h in control untreated wells, and T0 being the
absorbance in control wells measured immediately before drug
treatment. Each experiment was performed in triplicate, and IC50
values were estimated by linear interpolation at r = 0.5. We have
shown that the optimal seeding density was 1500 cells per well,
which resulted in an exponentially growing, subconfluent cell
layer at 72 h after seeding. The fibroblasts used in these studies
have a doubling time of approximately 24 h. Preliminary experi-
ments indicated that an incubation time of 3 days, corresponding
approximately to three cell doublings, resulted in reproducible
treatment-induced changes in cell growth.
RESULTS
Effect of cisplatin and oxaliplatin on JNK1 activity in
HCT116 cells
Figure 1 shows the structures of cisplatin and oxaliplatin. During
intracellular aquation, the chloride groups are released from
cisplatin and the oxalate group from oxaliplatin. Following reac-
tion with DNA, the adducts differ by virtue of the fact that the
cisplatin adduct has two amino groups projecting into the major
groove whereas the oxaliplatin adduct retains the bulkier DACH
ring. The major adducts formed by oxaliplatin are the Pt-GG and
Pt-AG intrastrand cross-links (Saris et al, 1996). Sedimentation
analysis showed that oxaliplatin does not induce detectable inter-
stand cross-links but forms DNA strand breaks (Woynarowski et
al, 1997). In contrast, cisplatin produces interstand crosslinks but
no breaks. Oxaliplatin appears to be less reactive with cellular
DNA than cisplatin, but is a comparably potent inhibitor of DNA
and protein synthesis (Saris et al, 1996; Woynarowski et al, 1997).
We have previously shown that cisplatin activates JNK kinase
more efficiently in DNA mismatch repair-proficient than repair-
deficient cells (Nehme et al, 1997). We have now conducted a new
set of experiments to directly compare the effects of cisplatin and
oxaliplatin on JNK1 activity. HCT116+ch2 and HCT116+ch3 cells
were exposed to 25 mM cisplatin or 30 mM oxaliplatin for 1 h, and
lysates prepared at 2 h after the beginning of drug exposure were
precipitated with anti-JNK1 antibody. GST-c-Jun (1—79) was used
as a substrate to determine the kinase activity of immune
complexes (Derijard et al, 1994). A low level of GST-Jun phos-
phorylation was detectable in the anti-JNK1 immunoprecipitates
obtained from untreated cells (Figure 2, lanes 1 and 4). In accor-
dance with our previous finding (Nehme et al, 1997), cisplatin
activated JNK1 kinase more efficiently in the repair-proficient
subline HCT116+ch3 [8.6 ± 2.5 (s.d.)-fold activation] than in the
repair-deficient HCT116+ch2 subline [1.5 ± 1.1 (s.d.)-fold activa-
tion] (Figure 2, lanes 2 and 5). However, oxaliplatin failed to acti-
vate JNK1 in either DNA mismatch repair-proficient or -deficient
HCT116 cells (Figure 2, lanes 3 and 6). In three separate experi-
ments, neither cisplatin nor oxaliplatin induced significant changes
in JNK1 protein levels. Therefore, the increase in activity induced
by cisplatin was due to activation of the enzyme because there was
no significant effect of cisplatin on JNK1 protein level.
Effect of cisplatin and oxaliplatin on JNK1 activity in
HEC59 cells
A second pair of mismatch repair-deficient (HEC59) and -profi-
cient (HEC59+ch2) cell lines was used to further compare the acti-
vation of JNK1 by cisplatin and oxaliplatin. We have previously
shown that cisplatin failed to activated JNK1 activity in mismatch
repair-proficient and -deficient HEC59 cells (Nehme et al, 1997).
We directly compared the effects of cisplatin and oxaliplatin on
JNK1 activity in HEC59 cells. In this cell system, there was no
detectable activation of JNK1 after cisplatin or oxaliplatin treat-
ment (Figure 2, lanes 7—12). Moreover, cisplatin and oxaliplatin
had no detectable effect on JNK1 levels (Figure 2). These results
suggest that the response to these two drugs is defective in both
deficient and proficient HEC59 cells. UV-C light, a potent inducer
of JNK1 (Derijard et al, 1994), did produce activation of JNK1
kinase in both types of HEC59 cells (data not shown), indicating
that JNK1 is functionally expressed but not activated by cisplatin
or oxaliplatin in the HEC59 cells.
Effect of cisplatin and oxaliplatin on c-Abl activity in
HCT116 cells
The observation that cisplatin activates the nuclear c-Abl tyrosine
kinase has been documented in several recent reports (Kharbanda et
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al, 1995; Liu et al, 1996a), and, as cisplatin fails to activate JNK in
c-Abl-deficient cells, the latter would appear to be located upstream
of JNK in this injury response pathway (Kharbanda et al, 1995). We
have previously shown that cisplatin activates c-Abl in mismatch
repair-proficient but not in mismatch repair-deficient cells (Nehme
et al, 1997). We compared the effect of cisplatin and oxaliplatin
directly on c-Abl kinase activity. HCT116+ch2 and HCT116+ch3
cells were treated with 25 mM cisplatin or 30 mM oxaliplatin for 1 h,
and anti-Abl immunoprecipitates were prepared from cell lysates at
2 h. In vitro kinase assays were performed with the GST-CTD
protein as substrate (Baskaran et al, 1996). A low level of GST-
CTD phosphorylation was detectable in the untreated cells (Figure
3, lanes 1 and 4), and the extent of GST-CTD phosphorylation
increased by a factor of 4.1 ± 0.3 (s.d.)-fold at 2 h after the begin-
ning of cisplatin exposure in the HCT116+ch3 proficient cells
(Figure 3, lane 2). In contrast, there was no induction of c-Abl
kinase activity in the mismatch repair-deficient HCT116+ch2 cells
exposed to cisplatin (Figure 3, lane 5). More importantly, there was
no detectable induction of GST-CTD phosphorylation when the
HCT116 DNA mismatch repair-proficient and -deficient cells were
exposed to oxaliplatin (Figure 3, lanes 3 and 6). The finding that
cisplatin had no detectable effect on c-Abl protein level indicated
an increase in c-Abl activity (Figure 3, lane 2).
Effect of cisplatin and oxaliplatin on c-Abl activity in
HEC59 cells
The cisplatin- and oxaliplatin-induced c-Abl tyrosine kinase
activity was also studied in the HEC59 and HEC59+ch2 cells.
Exposure of the mismatch repair-proficient HEC59+ch2 cells to
cisplatin produced a 4.5 ± 0.4 (s.d.)-fold stimulation of c-Abl
kinase activity at 2 h after the beginning of drug exposure (Figure
3, lane 8). However, there was no detectable induction of GST-
CTD phosphorylation when the HEC59 DNA mismatch repair-
deficient cells were exposed to cisplatin (Figure 3, lane 11).
Oxaliplatin failed to induce GST-CTD phosphorylation in either
the DNA mismatch repair-proficient or -deficient HEC59 cells
(Figure 3, lanes 9 and 12). Immunoblot analysis with anti-Abl anti-
body showed no detectable effect of cisplatin or oxaliplatin on c-
Abl levels in either the HEC59 or HEC59+ch2 cell lines (Figure 3).
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Effect of c-Abl expression on sensitivity to cisplatin
and oxaliplatin
We investigated the effect of loss of c-Abl kinase expression on
cisplatin and oxaliplatin-induced growth inhibition using 3T3 cells
in which both c-abl alleles had been knocked out (3T3-Abl—/—) and
sublines molecularly engineered to express a wild-type copy of c-
Abl (3T3-Abl+) or mock infected as a control (3T3-mock). Figure
4 shows the relative growth rate as a function of drug concentra-
tion for cisplatin and oxaliplatin for the three mouse fibroblast cell
lines. The results demonstrate that there was no difference in sensi-
tivity between the c-abl-null 3T3-mock cells and the reconstituted
3T3-Abl+ cells for cisplatin (IC50 21.4 ± 0.8 for 3T3-mock cells
and 22.7 ± 1.5 for 3T3-Abl+ cells). Similar results were obtained
with oxaliplatin (IC50 8.5 ± 1.2 for 3T3-mock cells and 8.3 ± 0.5
for 3T3-Abl+ cells).
DISCUSSION
We have previously shown that activation of JNK and c-Abl by
cisplatin is dependent on the integrity of DNA mismatch repair
function (Nehme et al, 1997). The hypothesis is that DNA
mismatch repair proteins serve as a detector for DNA damage due
to cisplatin but not oxaliplatin (Hawn et al, 1995; Kat et al, 1995);
resistance to cisplatin is linked to the failure of DNA mismatch
repair-deficient cells to recognize cisplatin adducts and to activate
signalling pathways that eventually trigger apoptosis. If this
hypothesis is correct, then the detector function of the mismatch
repair proteins must be able to initiate activation of signal trans-
duction pathways in response to cisplatin but not oxaliplatin. The
present work identifies JNK1 and c-Abl as members of pathways
activated by the detector function of the mismatch repair proteins
in response to cisplatin- but not oxaliplatin-induced cellular injury.
In the hMLH1-defective HCT116 colon cell model, cisplatin
caused a 5.7-fold greater increase in JNK1 activity in the mismatch
repair-proficient than in the -deficient cells. In contrast, oxaliplatin
did not activate JNK1 kinase in either DNA mismatch repair-profi-
cient or -deficient cells. Cisplatin and oxaliplatin failed to activate
JNK1 in either the repair-proficient or -deficient HEC59 endome-
trial cells, so that a differential effect could not be further docu-
mented in a second mismatch repair-proficient and -deficient cell
pair. Nevertheless, the data from the HCT116 mismatch repair-
proficient and -deficient cells argue that, in cells in which the
JNK1 pathway is triggered, mismatch repair activity is required
for maximal activation in response to cisplatin- but not oxaliplatin-
induced injury. In the case of c-Abl, cisplatin produced a 4.1- and
4.5-fold increase in activity in the proficient cells of both pairs
(HCT116+ch3 and HEC59+ch2 cells), that was completely
ablated by loss of DNA mismatch repair function in both types of
cells (HCT116+ch2 and HEC59). Thus, cisplatin consistently acti-
vated c-Abl and this activation was consistently mismatch repair
dependent in the two pairs of cell lines examined. In contrast,
oxaliplatin failed to activate c-Abl irrespective of the mismatch
repair status of the cells. The biochemical mechanisms that link
DNA mismatch repair proteins to the activation of the JNK1 and
c-Abl pathways have yet to be identified. Both JNK1 and c-Abl
have established nuclear functions and places these molecules in a
position where they can provide such coupling independent of the
activation status of cytoplasmic mitogen activated protein kinases
(Kipreos and Wang, 1992; Cavigelli et al, 1995).
The failure of cisplatin to activate JNK at concentrations that
produced an increase in c-Abl activity in the HEC59 cell system
suggests that these kinases are not part of the same signalling
pathway, and that JNK1 activation is not a universal feature of the
cisplatin-induced cellular injury response. These conclusions are
consistent with recent observations of Liu et al (1996a), who
showed that activation of c-Abl and JNK represent distinct
signalling responses to DNA damage. Failure of JNK1 activation
in HEC59 cells may be related to the fact that these cells exhibit
microsatellite instability (Umar et al, 1994), and it is possible that
there has been mutational inactivation of some proteins upstream
of JNK in the signalling response to cisplatin. Cisplatin and oxali-
platin kill cells by activating apoptosis (Chen et al, 1996;
Woynarowski et al, 1997); however, the fact that cisplatin and
oxaliplatin failed to activate JNK at concentrations that produced
apoptosis in either the HEC59 or HEC59+ch2 cells suggests that
JNK activation is not essential to successful initiation of apoptosis
by these drugs. This is consistent with recent evidence indicating
that JNK is not on the critical pathway by which apoptosis is acti-
vated in human breast cancer cells exposed to TNF (Liu et al,
1996b). No other information is currently available on the role that
JNK activation plays in platinum drug-induced apoptosis.
Although the role of the ATM (ataxia telangiectasia mutated)
gene product as an upstream activator of c-Abl during the cellular
injury response to radiation has recently been elucidated (Baskaran
et al, 1997; Shafman et al, 1997), there is limited information
about how c-Abl kinase actually triggers apoptosis in response to
this type of cellular injury. Recent studies by Yuan et al (1997)
have demonstrated that mouse embryonic fibroblasts deficient in
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Figure 4 Effect of the loss of c-Abl kinase on sensitivity to cisplatin (A) and
oxaliplatin (B). 3T3-Abl–/–(n n), 3T3-mock (l l), and 3T3-Abl+/+ (l) cells were
treated with appropriate concentrations of cisplatin or oxaliplatin for 1 h. The
cisplatin- and oxaliplatin-induced growth inhibition was determined by using
the sulphorhodamine B growth rate assay. Each data point represents the
mean of five independent experiments performed with triplicate culture, bars
represent standard deviationsc-Abl kinase are more resistant to the killing effects of ionizing
radiation compared with the wild-type cells, although this has not
been consistently observed (Liu et al, 1996a). The overexpression
of c-Abl inhibits growth by causing cell cycle arrest, and this
growth-suppressive activity is functionally similar to that of
tumour suppressor genes such as p53 and Rb (Sawyers et al, 1994;
Mattioni et al, 1995). Despite the fact that cisplatin consistently
activates c-Abl, it is not clear that such activation is required for
the triggering of apoptosis as the c-abl -null 3T3-mock cells are
not significantly resistant to this drug when compared with the
reconstituted 3T3-Abl+ cells. This is consistent with recent work of
Liu et al (1996a) who showed that loss of c-Abl does not
contribute to increased cisplatin-sensitivity. Thus, it is likely that
the mismatch repair system also triggers other pathways more
directly coupled to the generation of proapoptotic activity.
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